Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y014436 | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y015559 | OT |
No additional AEs; Caller reported patient received PROQUAD and VARIVAX at same office visit.; This spontaneous report was received from a physician assistant (reported as medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs and allergies were not reported. On 06-May-2025, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA [recombinant Human albumin]) (PROQUAD) injection, 0.5 mL, administered subcutaneously as prophylaxis (Lot No. Y014436 has been verified to be a valid lot number for [measles, mumps, rubella and varicella (oka-merck) virus vaccine live], expiration date reported and upon internal validation established as 22-Feb-2026) (strength, dose number, anatomical location of administration and vaccination scheme frequency were not provided); also with a dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection 0.5 mL, administered subcutaneously as prophylaxis (Lot No. Y015559 has been verified to be a valid lot number for [varicella virus vaccine live (oka-merck)], expiration date reported and upon internal validation established as 16-Sep-2026)(strength, dose number, anatomical location of administration and vaccination scheme frequency were not provided); both doses were reconstituted with sterile diluent solution for injection (BAXTER STERILE DILUENT) administered subcutaneously (Lot No., expiration date and indication were not provided). It was stated that the patient received both doses of previous mentions vaccines at the same office visit (overdose). No additional adverse events were reported (no adverse event).
Sterile diluent